20μg重组乙型肝炎疫苗在≥16岁健康人群中的9年免疫持久性研究  

A 9-year study on the immune persistence of 20μg recombinant hepatitis B vaccine in healthy people over 16 years old

作　　者：史云凤 张力 孟繁岳[1] 郑景山 梁祁[1] 李华宇 李靖欣[1,2] 李娟 甘建辉[4] 朱凤才 SHI Yun-feng;ZHANG Li;MENG Fan-yue;ZHENG Jing-shan;LIANG Qi;LI Hua-yu;LI Jing-xin;LI Juan;GAN Jian-hui;ZHU Feng-cai(Jiangsu Provincial Center for Disease Control and Prevention,Institute of Vaccine Assessment,Jiangsu Nanjing 210009,China;不详)

机构地区：[1]江苏省疾病预防控制中心疫苗临床评价所,江苏南京210009 [2]南京医科大学公共卫生学院全球健康中心 [3]深圳康泰生物制品股份有限公司 [4]江苏省疾病预防控制中心国家卫生健康委员会肠道病原微生物重点实验室

出　　处：《江苏预防医学》2021年第2期150-152,共3页Jiangsu Journal of Preventive Medicine

基　　金：艾滋病和病毒性肝炎等重大传染病防治(2018ZX10721202)。

摘　　要：目的评估20μg重组乙型肝炎疫苗在≥16岁人群中的免疫持久性。方法以9年前完成全程接种20μg重组乙型肝炎疫苗且免后抗-HBs阳转者为研究对象,采集静脉血,检测HBsAg和抗-HBs水平,采用描述性流行病学方法进行统计分析。结果共纳入研究586人,其中男性266人(45.4%),平均年龄53.3岁;女性320人(54.6%),平均年龄52.8岁。抗-HBs≥10mIU/ml共422人,阳性率为72.01%;≤50岁组抗-HBs的几何平均浓度(GMC)为34.31mIU/ml,>50岁组为27.00mIU/ml。结论该疫苗对于≥16岁人群的保护效果较好,无需加强免疫。Objective To evaluate the immune persistence of 20μg recombinant hepatitis B vaccine in people over 16 years old.Methods The cases completed the whole course of vaccination with 20μg recombinant hepatitis B vaccine 9 years ago who turned to HBs antibody positive were selected as the research subjects;whose venous blood samples were collected and subject to analysis for HBsAg and HBs antibody levels.The descriptive epidemiological method was used for statistical analysis.Results A total of 586 subjects were recruited,including 266 males(45.4%),with average age of 53.3 years;320 females(54.6%),with average age of 52.8 years.There were 422 subjects showed positive results for HBs antibody level≥10 mIU/ml,resulting positive rate of 72.0%;the geometric mean concentration(GMC)level of HBs antibody was 34.31 mIU/ml in group younger than 50 years old and 27.00 mIU/ml in group older than 50 years old.Conclusion The vaccine has a good protective effect for people over 16 years old.There is no need for boosted immunization.

关 键 词：乙型肝炎 疫苗 免疫持久性 

分 类 号：R512.6[医药卫生—内科学]